In another review of 500 patients with OM breast cancer treated with RT, clinical factors predictive of a favorable response to RT included HR+/HER2- subtype, solitary metastasis, bone-only metastasis, and long metastasis-free interval [29]. This evidence concerns the gene HR and breast cancer.